Advertisement
Since April 2002, Mr. Ross has been a consultant to early stage businessesand a financial investor. Since July 2005 he has also served as ExecutiveDirector, Greater New York for World Vision. His business career hasincluded senior financial officer and board member positions with both publicand private companies in diverse industries. Mr. Ross was Executive VicePresident and Chief Financial Officer and a board member of Tier TechnologiesInc. from February 1997 to January 2000, which became a public company duringthis period. Mr. Ross was a partner and investor with Capital Partners from1992 to 1997, serving on multiple boards of directors. He was a seniorfinancial officer and director of various Axel Johnson Inc. businesses from1979 to 1992. He also served as Executive Vice President and Chief FinancialOfficer and director of Aminoil USA, an R.J. Reynolds ("RJR") subsidiary, from1976 to 1979; and in various financial positions with RJR from 1969 to 1976.He also has worked in public accounting with Ernst & Ernst. Mr. Ross is aCertified Public Accountant and earned a Bachelor of Arts degree from OhioWesleyan University and a Masters of Business Administration from Ohio StateUniversity.
Advertisement
About Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engagedin research, development and manufacture of innovative Aversion(R) (abusedeterrent) Technology and related product candidates.
Forward Looking Statements
This press release contains "forward-looking statements" as defined in thePrivate Securities Litigation Reform Act of 1995. These statements are basedon current expectations of future events. If underlying assumptions proveinaccurate or unknown risks or uncertainties materialize, actual results couldvary materially from the Company's expectations and projections. The mostsignificant of such risks and uncertainties include, but are not limited to,the ability of the Company, King Pharmaceuticals Research and Development,Inc. and other pharmaceutical companies, if any, with whom the Company maylicense its Aversion(R) Technology, to obtain necessary regulatory approvalsand commercialize products utilizing the Aversion(R) Technology, the abilityto avoid infringement of patents, trademarks and other proprietary rights ortrade secrets of third parties, the ability to manufacture products utilizingthe Aversion(R) Technology, and the ability to fulfill the FDA's requirementsfor approving the Company's product candidates for commercial distribution inthe United States, including, without limitation, the adequacy of the resultsof the clinical studies completed to date and the results of other clinicalstudies, to support FDA approval of the Company's product candidates, theadequacy of the development program for the Company's product candidates,changes in regulatory requirements, adverse safety findings relating to theCompany's product candidates, the risk that the FDA may not agree with theCompany's analysis of its clinical studies and may evaluate the results ofthese studies by different methods or conclude that the results of the studiesare not statistically significant, clinically meaningful or that there werehuman errors in the conduct of the studies or otherwise, the risk that furtherstudies of the Company's product candidates are not positive, and theuncertainties inherent in scientific research, drug development, clinicaltrials and the regulatory approval process. You are encouraged to reviewother important risk factors relating to the Company on our web site atwww.acurapharm.com under the link, "Company R
